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ABSTRACT 
Objective: To develop precise LC-MS method for the estimation of valsartan impurities and perform validation as per ICH guidelines.  
Methods: Valsartan (VLN) and its degradation products were analyzed by reverse phase high-performance liquid chromatography (RP-HPLC) using 
mobile phase water: acetonitrile: glacial acetic acid: phosphate buffer in the ratio of 500:500:1:0.5 v/v/v/v at 225 nm using column nucleosil C18, 
125 ×4.0 mm, 5 µm. VLN sample (VLN SPL) thus obtained an unknown major impurity (UIMP) of 0.5 % at 0.38 retention time ratio (RRt) and purity 
of VLN was found to be 98.70 % respectively.  
Results: Estimation of VLN SPL total unknown impurities was found to be 1.3% by RP-HPLC. In similarly by liquid chromatography mass 
spectroscopy (LC-MS) a typical chromatogram of valsartan (VLN) at Rt 9.03 min and UIMP at Rt 3.3 min were recorded at a total run time of 23 min. 
Assay of VLN SPL was validated as per international council for harmonization (ICH) guidelines. Average % recovery was found to be 100.04 % for 
VLN SPL.  
Conclusion: The proposed work clearly indicates that the method can be easily adapted for the routine one step estimation of VLN active 
pharmaceutical ingredient (API). 
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Valsartan (VLN) [1-3] is a potent and highly selective oral drug that 
blocks the vasoconstrictor and aldosterone-secreting effects of 
angiotensin II by selectively blocking the binding of angiotensin II to 
the AT1 receptor in vascular smooth muscle and adrenal gland. It is 
chemicallyN-(1-oxopentyl)-N-[21-(1H-tetrazol-5-yl)-[1, 1-biphenyl]-4-
yl] methyl]-L-valine. The guidelines recommended by ICH [4] state 
that the acceptable levels for a known and UIMP in an API should be 
less than 0.15 and 0.10 %, respectively. In the development of VLN, 
various processes of related IMP were observed. The reported 
literature includes an increasing number of publications, 
developments of analytical methods for analysis of tablets and 
biological samples by HPLC [5, 6], UPLC [7] and LC-MS [8, 9] methods. 
However, only few reports were found in the literature for the 
identification of IMP in VLN product. The previous established 
methods were found to have more Rt and total run time for analysis. 
The present study was aimed to develop for the identification and 
development of IMP by using RP-HPLC and LC-MS method in VLN 
sample. The structure of VLN and predicted UIMP structure was 
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Fig. 1: Structure of valsartan (I) and unknown impurity (II) 
 
MATERIALS AND METHODS 
Chemical and reagents 
Valsartan sample (VLN SPL) was obtained as a gift from Matrix (Mylan 
Pharmaceuticals) Lab Pvt Ltd, Hyderabad. glacial acetic acid, methanol, 
and acetonitrile are obtained from Merck chemicals, Mumbai.  
Preparation of sample solutions 
Accurately weighed about 50 mg of VLN SPL was transferred into a 
100 ml volumetric flask, dissolve and make up to the mark with the 
mobile phase. Mobile phase mixture consists of water, acetonitrile, 
glacial acetic acid and phosphate buffer in the ratio of 500:500:1:0.5 
v/v/v/v. 
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Instrumentation and chromatographic conditions 
Shimadzu LC-20AD series HPLC and EZChrom Agilent 1100 HPLC 
were used. All weighing was done on Mettler toledo microbalance. 
LC-20AD series HPLC from Shimadzu technologies consists of an 
autosampler (Shimadzu SIL-HTC), LC-20AD serial pump, DGU-20A3 
prominence degasser; analytical column nucleosil C18 HT (125 
mm×4.0mm) 5 µm with a flow rate of 0.400 ml min-1. Data 
acquisition system and quantization program of applied biosystems 
analysis software version 1.5 was used for the determination of VLN 
and IMP. LC-MS analysis was performed on an API 5500 LC-MS 
triple quadrupole mass spectrometer equipped with an electrospray 
ionization (ESI) interface with turbo ion spray. The positive ions 
were measured in MRM mode (ion source 5500 v, declustering 
potential 57 v, focusing potential 256 v, entrance potential 10 v) for 
the analyte and IMP. The mass spectrometer was programmed to 
monitor the protonated molecule [M+H] for VLN at m/z 436 and for 
UIMP at m/z 352.  
Assay procedure 
Twenty tablets were weighed and crushed to fine powder. The 
tablet, powder equivalent to 50 mg of VLN working standard and 50 
mg of processed VLN SPL was transferred into a 100 ml volumetric 
flask and diluted with the mobile phase separator. 10 ml of this 
solution was a pipette out and diluted to 100 ml with the mobile 
phase and sonicated for 5 min. 
RESULTS AND DISCUSSION 
VLN SPL of 500 µg ml-1 was analyzed by HPLC using mobile phase at 
225 nm with a flow rate of 0.4 ml min-1. The percentage areas of 
related substances in the VLN SPL were recorded. The VLN SPL 
solution was injected into the LC-MS directly with the mobile phase 
and operates in positive ion mode. The chromatograms and 
spectrums were recorded. The previous reported HPLC [10-12] 
methods of VLN SPL and UIMP identification was found more Rt 
values when compared to proposed method, it shows that the 
proposed method was optimized and to separate more number of 
related IMP. A 10 µl of the VLN SPL solution was injected into the 
injector for six times under chromatographies condition. Area of 
each peak was measured at 225 nm. The amount of each drug 
present in the VLN SPL (n = 6) was determined from peak area and 
percent label claim and standard deviation (SD) was calculated as 
per ICH guidelines. The assay of observed results was shown in table 
1 and fig. 2.
 
Table 1: Assay of valsartan API and % recovery 
Drug Label claim (mg/tablet) Estimated % of labeled  
claim±SD 
% Recovery±SD 















VLN: valsartan standard; VLN SPL: valsartan sample; SD: standard deviation, n=6 
 
 
Fig. 2: Assay chromatogram of valsartan sample 
 
A typical chromatogram of VLN SPL was analyzed and recorded by RP-
HPLC and the purity of VLN was found to be 98.70 % and Rt 9.02 min, 
along with seven IMP peaks were identified at Rt of 3.46, 5.79, 6.73, 11.2, 
12.5, 15.8 and 20.38 min respectively. In that chromatogram was 
identified major amount of UIMP [13] was observed at 0.5 % at Rt 3.46 
and Rt ratio 0.38, which is higher than permissible limits of IMP limit. 
Total UIMP was found 1.3% as shown in fig. 3 and table 2. The VLN SPL 
was analyzed by LC-MS and the Rt of VLN and UIMP was found to be Rt 
9.03 min and 3.461 min respectively, which are obtained from spectral 
data at 225 nm. The data and structures were shown in the fig. 4.
  
Table 2: RP-HPLC chromatogram for valsartan 
Name Rt % Area Rt Ratio 
IMP 3.461 0.50 0.38 
Peak 2 5.798 0.31 0.65 
Rel. comp-B 6.734 0.28 0.74 
VLN SPL 9.024 98.70 1.00 
Peak 5 11.202 0.14 1.24 
Peak 6 12.517 0.02 1.38 
Peak 7 15.83 0.02 1.754 
Peak8 20.38 0.03 2.25 
Sum  100.0  
 Rt: retention time; VLN SPL: valsartan sample; IMP: impurity, n=6 
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Fig. 3: A typical RP-HPLC chromatogram of VLN SPL 
 
 
Fig. 4: A typical LC-MS chromatogram of VLN SPL 
 
From the analysis of spectral data of UIMP was determined by 
LC-MS method. From the above LC-MS Spectrum the m/z value 
of the IMP was suspected to be 352 (M+1) and XIC 
chromatogram was recorded at 352 amu and IMP eluted at Rt 
3.46 min. The major IMP was formed in the VLN is due to the 
alkaline hydrolysis (KOH) of amide group in the process of VLN 
synthesis. The molecular ion is 83 amu less than that of the mass 
of VLN. Protonated molecular ion at m/z 352 (M+1) confirms the 
IMP monoisotopic mass value of 351 corresponding to the 
molecular formula C19H21N5O2 and molecular weight of valeryl 
group is 83. Therefore, the IMP was formed with the elimination 
of valeryl group from VLN and mass fragmentation was carried 
for molecular ion of UIMP. The mass fragments of the IMP were 
detected at m/z 306, 235 and 207 repectively, which were 
similar to that of the fragments obtained at Rt 3.461 min in LC-
MS spectrum of the VLN and shown in table 3.
 
Table 3: MS data of valsartan sample 
Name LC-MS Rt (min) Precursor ion (m/z) Fragment ions (m/z) 
VLN 9.0 436 (M+H)+ 418,352,235,207 
IMP 3.461 352 (M+H)+,  
374 (M+Na)+,  
390 (M+K)+ 
306,235, 207 
VLN: valsartan; IMP: impurity; Rt: retention time 
 
The predicted structure of UIMP of VLN may be is (S)-N-(1-carboxy-
2-methylprop-1-yl)-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl] 
amine as shown in fig. 5. The assay of VLN SPL was developed and 
validated by RP-HPLC the results and % recovery was found to be 
100.04. The method is precise within the acceptance limit of 2% and 
result was shown in table 4.
 
Table 4: Assay of valsartan 




mean Sample Standard Sample Standard Sample Standard 
VLN  924478 900020 0.05021 0.05027 0.90 1.29 100 99.9 
 VLN: valsartan, n=6 
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Fig. 5: UIMP of VLN SPL fragmentation pattern structure 
 
CONCLUSION 
VLN SPL by RP-HPLC peak purity was identified as 98.70 %. The 
total related IMP were found 1.3 % by RP-HPLC. The intrinsic 
stability of VLN SPL and its related UIMP was identified by RP-HPLC 
and characterized by LC-MS. Proposed method development of VLN 
IMP was isolated. Total run time was 23 min and Rt of VLN API was 
9.3 min, when compared with the earlier reported method, this 
method was fast and accurate. The study focussed on the 
development chromatographies condition support to identification 
of a number of related IMP from the process development of VLN 
synthesis. The characterized IMP structure, analytical data was 
compared by the fragmentation pathway of the API. As per USP 
acceptance criteria assay of VLN should not be less than 98.0 % and 
not more than 102.0 % w/w on anhydrous basis and assay value 
was found to be within the limits. 
AUTHORS CONTRIBUTIONS 
All the authors have contributed equally 
CONFLICTS OF INTERESTS 
Declare none 
REFERENCES 
1. Nadeem S. Pharmacological and pharmaceutical profile of 
valsartan: a review. J Appl Pharm Sci 2011;4:12-9. 
2. Ulrich B. A high-throughput process for the synthesis of 
valsartan. Int J Res Pharm Chem 2007;11:892–8. 
3. N Rama Rao. Pharmaceutical impurities: an overview. Ind J 
Pharm Edu Res 2010;3:301-10. 
4. S Lakshmana Prabu . Impurities and its importance in 
pharmacy. Int J Pharm Sci Rev Res 2010;2:66-71. 
5. Kena H Patel. Simultaneous estimation of sacubitril and 
valsartan in the synthetic mixture by an RP-HPLC method. J 
Pharm Sci Bio Sci Res 2016;6:262-9. 
6. LRD Bhavani. Method development and validation of HPLC for 
determination of levetiracetan and valsartan in their 
formulations. Res Rev J Pharm Anal 2015;2:42-56. 
7. Ch Krishnaiah. Stability-indicating UPLC method for 
determination of valsartan and their degradation products in 
active pharmaceutical ingredient and pharmaceutical dosage 
forms. J Pharm Biomed Anal 2010;3:483-9. 
8. S Senthil Kumar. A validated gradient stability-indicating LC 
method for the analysis of valsartan in pharmaceutical dosage 
form. Int J Pharm Sci 2016;5:128-33. 
9. Mittal A. Design of experiment based optimized RP-HPLC 
method for simultaneous estimation of amlodipine and 
valsartan in bulk and tablet formulations. Austin J Anal Pharm 
Chem 2015;6:1-6. 
10. Subhajit G. RP-HPLC method for estimation of valsartan in solid 
oral dosage forms. J Pharm Sci Tech 2014;6:88-91. 
11. Sridevi Ramachandran. Stability-indicating HPLC method for 
simultaneous determination of valsartan and ezetimibe in 
pharmaceuticals. Trop J Pharm Res 2014;5:809-17. 
12. Tripti Sharma. Development and validation of a stability 
indicating RP-HPLC method for the determination of valsartan. 
Int J Pharm Sci 2015;7:57-61. 
13. Sunil Pai. A simple reverse phase-high-performance liquid 
chromatography method development and validation of 
valsartan in bulk and it’s tablet dosage form. Asian J Pharm Clin 
Res 2017;6:333-7.
 
